Smith Group Asset Management’s PTC Therapeutics PTCT Stock Holding History

Smith Group Asset Management’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-70	Closed	-$3K	–	341
2021 Q4	$3K	Hold	70	–	–	﹤0.01%	356
2021 Q3	$3K	Hold	70	–	–	﹤0.01%	364
2021 Q2	$3K	Hold	70	–	–	﹤0.01%	355
2021 Q1	$3K	Sell	70 -2,100	-97%	-$125K	﹤0.01%	319
2020 Q4	$132K	Hold	2,170	–	–	0.01%	196
2020 Q3	$101K	Hold	2,170	–	–	0.01%	198
2020 Q2	$110K	Sell	2,170 -30	-1%	-$1.47K	0.01%	189
2020 Q1	$98K	Hold	2,200	–	–	0.01%	215
2019 Q4	$106K	Hold	2,200	–	–	﹤0.01%	237
2019 Q3	$74K	Buy	2,200 +740	+51%	+$32.2K	﹤0.01%	252
2019 Q2	$66K	Hold	1,460	–	–	﹤0.01%	260
2019 Q1	$55K	Sell	1,460 -3,900	-73%	-$131K	﹤0.01%	296
2018 Q4	$184K	Buy	+5,360	New	+$193K	0.01%	249

Other funds holding PTCT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Smith Group Asset Management's PTCT Position: Q1 2022 in Review

Smith Group Asset Management sold out of PTC Therapeutics (PTCT) in Q1 2022, closing a stake of 70 shares — an estimated $3K sold.

Smith Group Asset Management first reported a position in PTCT in Q4 2018 and held it in 13 quarters. The position peaked at $184K in Q4 2018. 183 funds tracked by Wall St. Rank hold PTCT as of Q1 2022.

Smith Group Asset Management reported no remaining PTC Therapeutics position as of Q1 2022 after selling out during the quarter.
Smith Group Asset Management sold 70 PTC Therapeutics shares in Q1 2022, an estimated $3K.
Smith Group Asset Management first reported a position in PTC Therapeutics in Q4 2018 and held it in 13 quarters.
Smith Group Asset Management's PTC Therapeutics position peaked at $184K in Q4 2018.
183 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2022.

Based on Smith Group Asset Management's 13F filing for Q1 2022, filed 5 May 2022.